From the Desk of the Editor: Neal Shore

Neal Shore | February 26, 2018

Welcome to the timely new nmCRPCprostate cancer (nmCRPC) Center of Excellence.

Until February 2018 and the milestone ASCO GU presentations of the Phase III trials, A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER),


Neal Shore, MD, FACS

Neal Shore, MD, is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, and the Large Urology Group Practice Association. Dr. Shore is the editor-in-chief of UroToday’s print publication, Everyday Urology- Oncology Insights.

Conference Coverage
Recent data from conferences worldwide

ASCO GU 2019 Prostate Cancer

CUOS 2019 Prostate Cancer

SUO 2018 Prostate Cancer

AUA 2018 Northeastern Section

CUA 2018 Prostate Cancer

ASCO 2018 Prostate Cancer

AUA 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

An extensive resource of papers on urological diseases and conditions
Clinical Trials
Searchable database of currently enrolling clinical trials

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.